um

[Federal Register: August 12, 2002 (Volume 67, Number 155)]

[Proposed Rules]

[Page 52429-52431]

From the Federal Register Online via GPO Access [wais.access.gpo.gov]

[DOCID:fr12au02-19]

===============================================================

Proposed Rules

Federal Register

_________________________


ts

In a letter sent to FDA today (Aug. 12) CSPI urges the removal of a meat substitute, Quorn, from the market as well as a ban on further production. Quorn is a mold and can cause vomiting, diarrhea, hives, difficulty breathing, and dehydration according to over 30 U.S. and European consumer complaints. CSPI Press Release Quorn Meat Letter


ate information through print and electronic means, particularly their respective websites. Each party will also promote and encourage the participation of ATMI members in OSHA's cooperative programs, such as compliance assistance, the Voluntary Protection Program, Consultation, SHARP, and mentoring among ATMI members.

s'

News Release

U.S. Department of Labor

Occupational Safety and Health Administration

Office of Public Affairs

Washington, D.C.

For Immediate Release

Friday, Aug. 9, 2002

Contact: Frank Meilinger

Phone: (202) 693-1999

OSHA PROPOSES $288,000 IN PENALTIES AGAINST WEST VIRGINIA COMPANY FOLLOWING COMPREHENSIVE INSPECTION

Facility Targeted by Site-Specific Targeting Program


ar

CDER issues a guide to managing the benefits and risks of medicines. The guide compares the benefits and the risks of taking prescription drugs to those associated with driving a car. According to the guide, using a prescription could lower your blood pressure or give you an upset stomach; driving a car is more convenient than walking, but you could get in a costly accident. Click here for the guide.


te

FOR IMMEDIATE RELEASE

P02-25

August 12, 2002

Print Media: 301-827-6242

Consumer Inquiries: 888-INFO-FDA

FDA APPROVES ELOXATIN FOR COLORECTAL CANCER


/index.php?option=com_iwpfile&file=/dir_01/he2002_2142.pdf

HHS Secretary Tommy Thompson today (Aug. 9) issued a summary of its final rule providing patients more privacy protections for their medical records. HHS Release HHS Fact Sheet Privacy Rule


id

SCHERING-PLOUGH PRESS RELEASE

KENILWORTH, N.J., Aug. 8, 2002 Schering-Plough Corporation (NYSE: SGP) said today it disagreed with and would appeal a decision by a U.S. District Court Judge which found that certain claims of a patent protecting against generic versions of the nonsedating antihistamine CLARITIN (loratadine) and expiring in 2004 are not valid. The company maintains that the patent at issue protects CLARITIN-related products into 2004. The company is reviewing the decision of the Court that was issued early this afternoon.


/index.php?option=com_iwpfile&file=/dir_01/he2002_2139.pdf

Pages

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.